Healthcare / Drug Manufacturers - Specialty & GenericNYSE
$8.49
-0.63 (-6.91%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $35.8M · quality 39.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
48/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$438M
P/E
9.1x
↓EV/EBITDA
3.6x
↓ROE
10.1%
↑Gross Margin
53.7%
↑Debt/Equity
1.09
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+7.1%
FCF CAGR
—
FCF margin
22.2%
FCF / Net income
2.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $705.2M · net income $52.6M · FCF $156.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $705.2M | $705.2M | $1.01B | $1.02B | $1.08B | $1.77B | $1.56B | $1.11B | $782.4M | $560.9M | $488.8M | $489.3M | $404.5M | $312.7M | $281.9M | $273.4M | $286.2M | $234.8M |
| Net Income | $52.6M | $52.6M | $-190.6M | $-760.5M | $-211.6M | $219.5M | $305.8M | $54.5M | $62.7M | $82.6M | $51.8M | $62.9M | $36.7M | $31.1M | $23.5M | $23.0M | $51.7M | $31.1M |
| EBITDA | $237.9M | $237.9M | $36.9M | $-518.2M | $-38.4M | $465.2M | $488.6M | $163.6M | $126.1M | $156.5M | $133.5M | $165.3M | $111.5M | $59.8M | $41.2M | $41.5M | $79.5M | $45.1M |
| EPS | 0.93 | 0.93 | -3.60 | -14.85 | -4.47 | 4.06 | 5.68 | 1.04 | 1.22 | 1.71 | 1.13 | 1.41 | 0.88 | 0.85 | 0.65 | 0.64 | 1.59 | 0.99 |
| Gross Margin | 53.7% | 53.7% | 32.8% | 31.0% | 35.6% | 50.3% | 59.5% | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 15.9% | 15.9% | -8.0% | -19.7% | -15.2% | 19.2% | 28.2% | 10.3% | 11.5% | 22.2% | 21.6% | 28.9% | 22.1% | 13.7% | 10.6% | 11.7% | 25.7% | 17.1% |
| Net Margin | 7.5% | 7.5% | -18.8% | -74.3% | -19.7% | 12.4% | 19.7% | 4.9% | 8.0% | 14.7% | 10.6% | 12.8% | 9.1% | 10.0% | 8.3% | 8.4% | 18.1% | 13.3% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 1.09 | 1.09 | 1.37 | 1.32 | 1.01 | 0.50 | 0.58 | 0.73 | 0.78 | 0.01 | 0.42 | — | 0.45 | 0.13 | 0.13 | 0.13 | 0.08 | — |
| Current Ratio | 4.29 | 4.29 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $156.8M | $156.8M | $35.8M | $-257.9M | $-149.9M | $96.1M | $395.0M | $101.1M | $-30.3M | $153.3M | $-21.6M | $-2.3M | $81.6M | $54.9M | $-14.2M | $-41.8M | $75.9M | $-3.4M |
| Returns | ||||||||||||||||||
| ROE | 10.1% | 10.1% | -39.5% | -117.1% | -15.2% | 13.6% | 21.1% | 5.0% | 6.2% | 9.1% | 8.7% | — | 6.6% | 6.4% | 5.3% | 5.6% | 14.0% | — |
| Valuation | ||||||||||||||||||
| P/E | 9.13 | 9.13 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 3.56 | 3.56 | 30.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 0.92 | 0.92 | 1.13 | 0.17 | 0.49 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -30.4% | -30.4% | -0.9% | -4.9% | — | 14.0% | 40.6% | 41.4% | 39.5% | 14.8% | -0.1% | 21.0% | 29.3% | 10.9% | 3.1% | -4.5% | 21.9% | — |
| EPS Growth | 125.8% | 125.8% | 75.8% | -232.2% | — | -28.5% | 446.2% | -14.8% | -28.7% | 51.3% | -19.9% | 60.2% | 3.5% | 30.8% | 1.6% | -59.7% | 60.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-6.8%
EPS terminal req.
$0.75
Spread vs growth
132.6%
5Y implied EPS CAGR
-0.4%
EPS terminal req.
$0.91
Spread vs growth
126.2%
10Y implied EPS CAGR
4.7%
EPS terminal req.
$1.47
Spread vs growth
121.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.60 → 0.93
Residual
+34.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.